Combination pharmacotherapy for stopping smoking: what advantages does it offer?
Globally, tobacco kills almost 5 million people around the world annually. Seven first-line pharmacotherapies are currently available and recommended by the United States Public Health Service (USPHS) clinical practice guideline for treating tobacco dependence, all of which have been proven to be effective for increasing tobacco abstinence rates when used as monotherapy. However, not all smokers are able to quit with single-drug therapy. Some smokers may benefit from combination therapy that includes the simultaneous use of different nicotine replacement therapies (NRTs) or medications with different mechanisms of action (e.g. NRT and bupropion). Combination therapy with different types of NRT may provide a therapeutic advantage by increasing serum nicotine concentrations, and combination therapy with different drugs may capitalize on synergy obtained from two different mechanisms of action. However, controversy exists regarding this approach. Available data suggests that combination therapy may increase abstinence rates compared with monotherapy. However, the cost effectiveness of this approach has not been clearly demonstrated.
Ebbert
Jon O
JO
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. ebbert.jon@mayo.edu
Hays
J Taylor
JT
Hurt
Richard D
RD
D000818:Animals; D016642:Bupropion / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D009538:Nicotine / Q000008:administration & dosage / Q000031:analogs & derivatives; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012907:Smoking / Q000188:drug therapy* / Q000378:metabolism; D016540:Smoking Cessation / Q000379:methods*
D016642:Bupropion; D009538:Nicotine
Biol Psychiatry. 2008 Jun 1;63(11):1092-6
18096137
N Engl J Med. 1997 Oct 23;337(17):1195-202
9337378
Tob Control. 2006 Jun;15(3):152-9
16728744
Arch Gen Psychiatry. 2009 Nov;66(11):1253-62
19884613
J Clin Psychopharmacol. 2007 Aug;27(4):380-6
17632223
JAMA. 2006 Jul 5;296(1):56-63
16820547
JAMA. 2006 Jul 5;296(1):47-55
16820546
Trends Pharmacol Sci. 1992 May;13(5):177-84
1604710
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103
18646137
Arch Intern Med. 2009 Dec 14;169(22):2148-55
20008701
BMJ. 2008 May 31;336(7655):1223-7
18441375
Ann Intern Med. 2010 Feb 2;152(3):144-51
20124230
Drug Alcohol Depend. 2006 Apr 28;82(2):91-102
16188401
J Clin Pharmacol. 2006 Dec;46(12):1439-48
17101743
N Engl J Med. 1999 Mar 4;340(9):685-91
10053177
J Thorac Oncol. 2007 Mar;2(3):249-56
17410050
BMJ. 1999 Jan 30;318(7179):285-8
9924052
Nicotine Tob Res. 2009 Mar;11(3):234-9
19246427
Nicotine Tob Res. 2009 May;11(5):572-6
19351781
Alcohol. 2007 Aug;41(5):381-91
17889314
Arch Intern Med. 1999 Sep 27;159(17):2033-8
10510989
Nicotine Tob Res. 2003 Apr;5(2):181-7
12745490
CNS Drugs. 2001;15(6):453-67
11524024
Psychopharmacology (Berl). 2007 Feb;190(2):157-70
17115136
Thorax. 2008 Aug;63(8):717-24
18263663
Prev Med. 1995 Jan;24(1):41-7
7740014
Arch Intern Med. 2004 Nov 8;164(20):2229-33
15534159
Med Decis Making. 2002 Sep-Oct;22(5 Suppl):S26-37
12369228
Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000146
18253970
Mayo Clin Proc. 2007 Feb;82(2):186-95
17290726
Arch Intern Med. 2000 Nov 13;160(20):3128-34
11074742
Addiction. 2008 Jan;103(1):146-54
18028247
Psychopharmacology (Berl). 1993;111(3):271-7
7870963
Ann Intern Med. 2009 Apr 7;150(7):447-54
19349630
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000031
17253443